A new skin-applied gene therapy uses lipid nanoparticles to deliver gene editing into skin stem cells, correcting ...

OGM was selected as a genome-wide, unbiased method to detect large genomic rearrangements and structural variants (SVs) with sensitivity to variant allele fractions (VAFs) as low as 5% to analyze ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.

In November, six months after KJ’s debut, top Food and Drug Administration officials Marty Makary and Vinay Prasad published ...

Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible ...

Cellares will establish a standardized platform manufacturing process on the Cell Shuttle and platform release assays on the Cell Q.

U.S. drugmaker Eli Lilly and Company signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...